Solifenacin

• CAT Number: I012990
• CAS Number: 242478-37-1
• Molecular Formula: C₂₃H₂₆N₂O₂
• Molecular Weight: 362.46
• Purity: ≥95%
• Target: mAChR
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate
• InChI: InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1
• InChIKey: FBOUYBDGKBSUES-VXKWHMMOSA-N
• SMILES: C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5

Solifenacin (Cat No.: I012990) is a novel medication known as a muscarinic receptor antagonist. It exhibits a high affinity for specific subtypes of muscarinic receptors, including M1, M2, and M3 receptors, with pKi values of 7.6, 6.9, and 8.0, respectively. This selective antagonism of muscarinic receptors makes Solifenacin valuable in the treatment of overactive bladder and related conditions by reducing involuntary muscle contractions in the bladder. If you need to, please contact us in time, and we will reply to you as soon as possible within 24 hours.

Reference

[1]. Ikeda K, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol. 2002 Aug;366(2):97-103.[2]. Suzuki M, et al. Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infarctedrats. Eur J Pharmacol. 2005 Apr 4;512(1):61-6.